Physician profile
Michael Sayegh
NPI 1659339141
$12,937.38
in general payments reported to CMS, 2019-2025
29 companies · $1,727 in 2025
The $1,727 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,205 · 2020: $1,818 · 2021: $982 · 2022: $1,261 · 2023: $2,691 · 2024: $1,253 · 2025: $1,727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,268 · Consulting Fee: $1,400 · Education: $2.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,267.73 |
| Consulting Fee | $1,400.00 |
| Education | $2.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $7,307.52 | 2019-2025 | Ora System Verifeye, Lensx, Clareon Panoptix Pro |
| Abbvie INC. | $1,591.36 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Sun Pharmaceutical Industries INC. | $655.44 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $504.59 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $503.58 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $394.27 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $229.42 | 2024-2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $202.76 | 2020-2022 | |
| Sight Sciences, INC. | $180.06 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Harrow Eye, LLC | $169.20 | 2024-2025 | Vevye |
| Glaukos Corporation | $153.40 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $145.18 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $134.74 | 2019-2021 | |
| Allergan, INC. | $130.37 | 2020-2021 | |
| Dompe US, INC. | $104.87 | 2024-2025 | Oxervate |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $79.46 | 2023 | Variax, Reunion, Axsos |
| Ocular Therapeutix, INC. | $55.61 | 2020-2021 | |
| New World Medical,INC. | $52.15 | 2021 | |
| Shire North American Group INC | $46.15 | 2019 | |
| Rayner Intraocular Lenses Limited | $45.58 | 2022-2024 | Rayone Spheric, Omidria, Rayone Aspheric |
| Thea Pharma INC. | $42.05 | 2023-2024 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $40.26 | 2020-2021 | |
| Eyepoint US, INC. | $35.48 | 2019-2020 | |
| Lkc Technologies, INC. | $35.06 | 2025 | |
| Beaver-Visitec International, INC. | $25.37 | 2025 | |
| Johnson & Johnson Surgical Vision, INC. | $21.17 | 2019 | |
| Lensar, INC. | $18.50 | 2023 | Lensar Laser System |
| Rxsight INC | $16.98 | 2021 | |
| Biotissue Holdings INC. | $16.80 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sayegh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.